Nerandomilast in Patients with Progressive Pulmonary Fibrosis

T Toby M. Maher S Shervin Assassi A Arata Azuma (Clinical Research Center, Mihara General Hospital, Saitama, Japan) V Vincent Cottin (Université Claude Bernard Lyon 1, Lyon, France) A Anna-Maria Hoffmann-Vold (Department of Rheumatology, Oslo University Hospital, Oslo) M Michael Kreuter (Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany) J Justin M. Oldham (Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor) L Luca Richeldi (Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome) C Claudia Valenzuela (Department of Pulmonology, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid) M Marlies S. Wijsenbeek E Emmanuelle Clerisme-Beaty (Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany) C Carl Coeck (Boehringer Ingelheim, Brussels) H Hui Gu (Department of Chemistry and Chemical Engineering) I Ivana Ritter (Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany) A Arno Schlosser (Clinical Development Operations, Boehringer Ingelheim, Amsterdam) S Susanne Stowasser (Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany) F Florian Voss (Global Biostatistics and Data Sciences, Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany) G Gerrit Weimann (Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany) D Donald F. Zoz (Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT) F Fernando J. Martinez

Article Details

Volume / Issue Vol. 392, Issue 22
Published June 12, 2025
Pages 2203-2214
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (20)

T

Toby M. Maher

S

Shervin Assassi

A

Arata Azuma

Clinical Research Center, Mihara General Hospital, Saitama, Japan

V

Vincent Cottin

Université Claude Bernard Lyon 1, Lyon, France

A

Anna-Maria Hoffmann-Vold

Department of Rheumatology, Oslo University Hospital, Oslo

M

Michael Kreuter

Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, Mainz, Germany

J

Justin M. Oldham

Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor

L

Luca Richeldi

Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome

C

Claudia Valenzuela

Department of Pulmonology, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Madrid

M

Marlies S. Wijsenbeek

E

Emmanuelle Clerisme-Beaty

Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

C

Carl Coeck

Boehringer Ingelheim, Brussels

H

Hui Gu

Department of Chemistry and Chemical Engineering

I

Ivana Ritter

Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

A

Arno Schlosser

Clinical Development Operations, Boehringer Ingelheim, Amsterdam

S

Susanne Stowasser

Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

F

Florian Voss

Global Biostatistics and Data Sciences, Boehringer Ingelheim Pharma, Ingelheim am Rhein, Germany

G

Gerrit Weimann

Therapy Area Inflammation Medicine, Boehringer Ingelheim International, Ingelheim am Rhein, Germany

D

Donald F. Zoz

Global Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT

F

Fernando J. Martinez